Proactive Investors - Run By Investors For Investors

Hemispherx Biopharma posts reminder of deadline for $8M rights issue

Ownership of Hemispherx stock must occur on February 12 to allow for participation in the $8 million rights offering
vials in a lab
Hemispherx’s flagship product is the Argentina-approved Ampligen, which treats chronic fatigue syndrome and cancerous tumors

Hemispherx Biopharma Inc (NYSEAmerican:HEB) on Tuesday issued a reminder to its stockholders that the record date of its proposed $8 million rights offering is Thursday, February 14.

To be a stockholder of record on the record date, ownership of Hemispherx stock must occur before the market closes on February 12 to account for settlement.

READ: Hemispherx Biopharma launches $8M rights issue to fund cancer drug trials

Under the terms of the rights offering, Hemispherx will distribute to holders of its stock as well as holders of certain options and warrants as of February 14 at no charge, one non-transferable subscription right for each share of stock held or deemed held on the record date.

Each right allows the shareholder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series B Convertible Preferred stock with a face value of $1,000 (and immediately convertible into common stock at a conversion price of $0.25) and 4,000 five-year warrants with an exercise price of $0.25.

Subscription rights are non-transferable and may only be exercised during the subscription period of Friday, February 15, 2019, through Friday, March 1, 2019, unless extended by Hemispherx.

Hemispherx’s flagship products include the Argentina-approved Ampligen, which treats chronic fatigue syndrome and cancer, and the FDA-approved drug Alferon N Injection, a treatment for genital warts.

Hemispherx traded up 1% at US$0.24 in afternoon trade on Tuesday.

Contact Ellen Kelleher at [email protected]


View full HEB profile View Profile

Hemispherx Biopharma Timeline

Related Articles

scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use